Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma

Abstract

Temozolomide in combination with interferon is a well-tolerated palliative regimen that has moderate activity against metastatic melanoma. Further evaluation of this regimen in comparative studies or in combination with other drugs is warranted.